Therapy Areas: Autoimmune
Horizon Therapeutics plc announces Aaron Cox to succeed CFO Paul Hoelscher
3 November 2021 -

Horizon Therapeutics plc (Nasdaq: HZNP) reported on Wednesday that executive vice president, chief financial officer Paul Hoelscher will retire on 16 May 2022, but will continue as an advisor to the company through to May 2023.

The company has named Aaron Cox, who was named executive vice president, finance, as successor to Hoelscher.

Having joined Horizon in 2016, Cox has served in various roles across business development and corporate development.

Most recently he served as senior vice president, corporate development and chief of staff to Tim Walbert, chairman, president and chief executive officer, Horizon.

Previously, Cox was vice president, capital markets at BMO Capital Markets and held investment banking roles at JMP Securities and Stout.

Horizon focuses on the discovery, development and commercialisation of medicines for people suffering from rare, autoimmune and severe inflammatory diseases.

Login
Username:

Password: